Rise and shine, everyone, another busy day is on the way. This will, in fact, prove to be an especially busy one for us, since we will be ensconced in a day-long industry gathering. So posting today may be a bit spotty. Of course, breaking away from the trusty laptop can be a good thing, now and then. And we will be all eyes and ears as we practice our hobnobbing. Meanwhile, here are a few items of interest to help you on your own journey. Hope your day is productive and we look forward to catching up….

Merck (MRK) raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling Keytruda cancer treatment, Reuters reports. The list price increases are the first that the company made since pledging in July that it would not raise the average net price of all of its medicines by more than the inflation rate. A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Since there is no transparency on “all [Merck] medicines.” how shall we rate the truth of this statement. “A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.”
    For clarity it ranks with, “to the best of my recollection” – if below “I cannot recall, Senator.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy